Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 55150-393

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 55150-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Azacitidine-figure-1 (Azacitidine Fig1)

A Kaplan-Meier survival curve chart comparing proportion surviving over time in months from randomization between AZA (Azacitidine) and CCR groups. The chart includes a risk table showing the number of subjects at risk at various time points. The AZA group shows higher survival compared to the CCR group, with statistical data including a log-rank p-value of 0.0001 and hazard ratio of 0.58 (95% CI: 0.43-0.77).*

FDA Label Image

Package Label-principal Display Panel-100 mg Per Vial (Container Label)

Label for Azacitidine for Injection 100 mg per vial, a lyophilized powder for injection by intravenous or subcutaneous use. The single-dose vial contains 100 mg azacitidine and mannitol, labeled as a cytotoxic agent. Manufactured for Eugia US LLC, with storage instructions and barcode included.*

FDA Label Image

Package Label-principal Display Panel-100 mg Per Vial (Container-Carton (1 Vial))

Azacitidine for Injection 100 mg per Vial powder label for injection by Eugia US LLC. The sterile single-dose vial label states azacitidine 100 mg and mannitol 100 mg. It is for subcutaneous and intravenous use only and lists storage instructions and handling warnings, including cytotoxic agent caution. The label includes the product NDC 55150-393-01 and distributor address in New Jersey.*

FDA Label Image

Chemical Structure (Azacitidine Str)

Chemical structure of azacitidine, showing its molecular framework including nitrogenous bases and hydroxyl groups, consistent with the active ingredient azacitidine used in injection powder form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.